Tg Therapeuticsincis A Biopharmaceutical Company Based In New York Cityit Focuses On Developing And Commercializing Innovative Therapies For B Cell Malignancies And Autoimmune Diseasesthe Company Operates Globallywith Activities In The Usaustraliaand The Ukone Of Its Key Products Is Briumvia Ublituximab Xiiy Which Is Approved For Treating Relapsing Forms Of Multiple Sclerosistg Therapeutics Is Also Advancing A Pipeline Of Clinical Stage Candidates Targeting B Cell Disordersincluding Ublituximaba Btk Inhibitortg 1701 And A Bispecific Antibodytg 1801 The Company Conducts Various Clinical Trials To Evaluate These Therapiesincluding Pivotal Studies For Briumvi In Multiple Sclerosis And Combination Therapies For Chronic Lymphocytic Leukemia Tg Therapeutics Primarily Serves Healthcare Providersincluding Neurologists And Oncologistsas Well As Patients With Relapsing Multiple Sclerosis And B Cell Cancersthe Company Also Supports Clinical Trial Recruitment And Offers Fellowship Grants To Promote Research And Professional Development In Its Therapeutic Areas
